Anew Theraputics
- Biotech or pharma, therapeutic R&D
Anew Therapeutics is the dedicated operational arm for ByteDance’s AI drug discovery initiatives
Mission: Leveraging ByteDance’s cutting-edge AI technology to develop breakthrough therapeutics beyond the reach of conventional approaches
Strategy: Develop oral small molecules for antibody-validated, protein-protein interaction (PPI) targets in immunology
Team : A global team of experienced drug discovery scientists and machine learning experts, based in Shanghai, San Francisco and Singapore
Technology Platforms:
- Molecular Generative Models – Exploration of vast and novel chemical space
- In Silico Evaluation Models – Accelerated iteration and rapid optimization of potency and drug properties
Pipeline: Four preclinical programs addressing immunological diseases with large patient populations.
Lead assets:
- An advanced small molecule IL-17A inhibitor nominated for preclinical development with novel scaffold.
- An IL17 A and F dual inhibitor in LO stage
Address
San JoseCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}